Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.

Hepatol Commun · 2023 · PMC10615429 · PMID 37889520

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, this did not reach statistical significance and median OS was similar between groups as well (11.6 vs. 11.4 mo). 13 Despite our promising findings regarding the efficacy and safety of atezolizumab and bevacizumab in subsequent treatment lines, our study has several limitations.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.